Payment overview · 2025
General Payments
$247.76
12 reported records · 6 companies
Healthcare provider profile · identity verified
Baljinder Singh Gill, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROSEVILLE, CA · NPI 1790774784
Verified facts
What the public records show
CMS Open Payments records show Baljinder Singh Gill, MD received $247.76 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 27.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.10 | 27.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.06 | 19.8% | 2 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $47.40 | 19.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.77 | 16.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.41 | 9.8% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.02 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $247.76 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.06 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.80 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.80 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 727 | 194 |
| Amlodipine Besylate | Amlodipine Besylate | 709 | 191 |
| Levothyroxine Sodium | Levothyroxine Sodium | 569 | 156 |
| Losartan Potassium | Losartan Potassium | 400 | 108 |
| Omeprazole | Omeprazole | 283 | 84 |
| Metformin Hcl | Metformin Hcl | 281 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 78 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 243 | 39 |
| Gabapentin | Gabapentin | 224 | 54 |
| Alprazolam | Alprazolam | 216 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 63 |
| Eliquis | Apixaban | 169 | 40 |
| Furosemide | Furosemide | 159 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 47 |
| Lisinopril | Lisinopril | 152 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 142 | 33 |
| Lorazepam | Lorazepam | 134 | 28 |
| Tramadol Hcl | Tramadol Hcl | 129 | 54 |
| Baclofen | Baclofen | 127 | 55 |
| Carvedilol | Carvedilol | 123 | 30 |
| Azithromycin | Azithromycin | 121 | 102 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 30 |
| Potassium Chloride | Potassium Chloride | 119 | 34 |
| Simvastatin | Simvastatin | 118 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 47 |
| Glimepiride | Glimepiride | 97 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 36 |
| Trazodone Hcl | Trazodone Hcl | 93 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 46 |
| Atenolol | Atenolol | 86 | 20 |
| Sertraline Hcl | Sertraline Hcl | 86 | 26 |
| Famotidine | Famotidine | 85 | 20 |
| Methylprednisolone | Methylprednisolone | 85 | 75 |
| Bupropion Xl | Bupropion Hcl | 79 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 62 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 18 |
| Metformin Hcl Er | Metformin Hcl | 70 | 23 |
| Montelukast Sodium | Montelukast Sodium | 70 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 56 |
| Januvia | Sitagliptin Phosphate | 64 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 63 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 18 |
| Allopurinol | Allopurinol | 60 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Ozempic | Semaglutide | 57 | 11 |
| Clonazepam | Clonazepam | 53 | 11 |
| Mirtazapine | Mirtazapine | 52 | 15 |
| Ezetimibe | Ezetimibe | 50 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Diazepam | Diazepam | 47 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 47 | 47 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Ibuprofen | Ibuprofen | 46 | 18 |
| Synthroid | Levothyroxine Sodium | 46 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 22 |
| Valacyclovir | Valacyclovir Hcl | 44 | 20 |
| Finasteride | Finasteride | 42 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Ramipril | Ramipril | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Spironolactone | Spironolactone | 37 | 12 |
| Temazepam | Temazepam | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Cefdinir | Cefdinir | 33 | 31 |
| Jardiance | Empagliflozin | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Meloxicam | Meloxicam | 30 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | 11 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 20 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Modafinil | Modafinil | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 12 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Tobramycin | Tobramycin | 14 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $247.76 · 12 records | Novo Nordisk Inc | Cologuard Collection Kit, Fluad, Flucelvax, KISUNLA, Ozempic, Rybelsus, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error